55623-27-3

Basic information

• Product Name: ENDO-TROPACOCAINE (8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL) BENZOATE HCL
• Synonyms: ENDO-TROPACOCAINE (8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL) BENZOATE HCL ;endo-Benzoic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester hydrochloride
• CAS NO: 55623-27-3
• Molecular Formula: C₁₅H₁₉NO₂*ClH
• Molecular Weight: 0
• Mol File: 55623-27-3.mol

Chemical Properties

• Boiling Point: 339.9°Cat760mmHg
• Flash Point: 122.3°C
• Appearance: /
• Density: 1.15g/cm³
• Vapor Pressure: 7.11E-06mmHg at 25°C
• CAS DataBase Reference: ENDO-TROPACOCAINE (8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL) BENZOATE HCL(CAS DataBase Reference)
• NIST Chemistry Reference: ENDO-TROPACOCAINE (8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL) BENZOATE HCL(55623-27-3)
• EPA Substance Registry System: ENDO-TROPACOCAINE (8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL) BENZOATE HCL(55623-27-3)

Safety Data

• Hazardous Substances Data: 55623-27-3(Hazardous Substances Data)

Usage

Uses

Used in Medical Industry:
ENDO-TROPACOCAINE (8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL) BENZOATE HCL is used as a local anesthetic for medical procedures and surgeries. It is used for its effective pain relief with a lower risk of side effects compared to other local anesthetics. Its reduced potential for abuse and addiction makes it a promising alternative to traditional anesthetics.
Used in Clinical Trials:
ENDO-TROPACOCAINE (8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL) BENZOATE HCL is used in clinical trials to study its potential as a safer alternative to traditional anesthetics. ENDO-TROPACOCAINE (8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL) BENZOATE HCL has shown promising results in these trials, indicating its potential for use in medical applications where effective pain relief is required.

InChI:InChI=1/C15H19NO2.ClH/c1-16-12-7-8-13(16)10-14(9-12)18-15(17)11-5-3-2-4-6-11;/h2-6,12-14H,7-10H2,1H3;1H/t12-,13+,14+;

Upstream product

• 98-88-4 benzoyl chloride 
• 120-29-6 3-tropanol 

Downstream Products

• 19145-60-9 endo-benzoic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester 

Relevant articles and documents

NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS

This invention relates to novel chromen-2-one derivatives of formula (I) useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. Formula (I) wherein Q represents a chromen-2-one group; which chromen-2-one group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; R1 represents hydrogen or alkyl; which alkyl is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; and R2 and R3 together form -(CH2)-(CH2)- or -(CH)=(CH)-.

Structural analysis of 5-HT3 receptor antagonists: Synthesis and pharmacological activity of various aromatic esters or amides derived from tropane and 1,2,6-trisubstituted piperidine

Preliminary results of a structure-activity relationship in the field of 5-HT3 receptor antagonists on the influence of the aromatic ring and steric hindrance around the basic nitrogen atom are reported. The favorable role of the naphthalene moiety substituted by a carbonyl function in position 1 was demonstrated by measuring the biological activity using the inhibition of the specific binding of [3H]BRL 43694 and the inhibition of the Bezold-Jarisch reflex. Several esters and amides of 1,2,6-trisubstituted piperidine derivatives with a suitable fit with the antagonist reference compounds were synthesized. The lack of biological activity of these compounds emphasizes the importance of steric hindrance for binding with the anionic receptor site. These data confirm the major role of the tropane and quinuclidine frameworks in the potency of a number of 5-HT3 antagonists.